ARS Pharmaceuticals, Inc. short interest in 2022
In 2022, ARS Pharmaceuticals, Inc.'s disclosed short interest ran from 4.62% of shares outstanding on 14 Jan 2022 to 2.35% on 31 Oct 2022, a change of -2.27 percentage points. The year's high was 4.71% on 31 Jan 2022 and its low 1.44% on 15 Aug 2022, averaging 2.82% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.95 days on 14 Oct 2022. Full history: ARS Pharmaceuticals, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 4.62% (14 Jan 2022)
- End of year
- 2.35% (31 Oct 2022)
- Change
- -2.27 pp
- High
- 4.71% (31 Jan 2022)
- Low
- 1.44% (15 Aug 2022)
- Average
- 2.82%
- Highest days to cover
- 8.95 (14 Oct 2022)
- SEC filings marked
- 6
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 4.62% | 5.27 | |
| 31 Jan 2022 | 4.71% | 4.63 | |
| 15 Feb 2022 | 4.71% | 5.96 | |
| 28 Feb 2022 | 4.68% | 5.44 | |
| 15 Mar 2022 | 2.52% | 4.29 | |
| 31 Mar 2022 | 1.89% | 2.29 | 10-K filed, results (8-K) |
| 14 Apr 2022 | 2.55% | 1.00 | |
| 29 Apr 2022 | 3.45% | 3.35 | |
| 13 May 2022 | 3.62% | 2.99 | 10-Q filed, results (8-K) |
| 31 May 2022 | 3.02% | 4.55 | |
| 15 Jun 2022 | 3.24% | 2.81 | |
| 30 Jun 2022 | 2.19% | 1.04 | |
| 15 Jul 2022 | 1.58% | 2.37 | |
| 29 Jul 2022 | 1.46% | 1.00 | |
| 15 Aug 2022 | 1.44% | 1.81 | 10-Q filed |
| 31 Aug 2022 | 1.52% | 3.56 | |
| 15 Sep 2022 | 1.53% | 4.79 | |
| 30 Sep 2022 | 2.81% | 4.04 | |
| 14 Oct 2022 | 2.53% | 8.95 | |
| 31 Oct 2022 | 2.35% | 3.06 |
See also: ARS Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.